Imidazo-pyridine compounds as PAD inhibitors

US11426412B2 · kind B2 · utility

Assignee

• JUBILANT EPIPAD LLC · US

Inventors

• Gurulingappa Hallur · Kanchinakote, IN
• Athisayamani Jeyaraj Duraiswamy · Singapore, SG
• Buchi Reddy Purra · Kanchinakote, IN
• N.V.S.K. RAO · Kanchinakote, IN
• Sridharan Rajagopal · Bengaluru, IN
• Rajendra Kristam · Noida, IN

Key dates

• Filing date: Oct 16, 2018
• Grant date: Aug 30, 2022
• Expiry date: Oct 16, 2038

Classification

• Technology area (CPC C): Chemistry; Metallurgy
• CPC primary: C07D498/04
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

Heterocyclic compounds of Formula (I), (II), and (III) are described herein along with their polymorphs, stereoisomers, prodrugs, solvates, co-crystals, intermediates, pharmaceutically acceptable salts, and metabolites thereof. The compounds described herein, their polymorphs, stereoisomers, prodrugs, solvates, co-crystals, intermediates, pharmaceutically acceptable salts, and metabolites thereof are PAD4 inhibitors and may be useful in the treatment of various disorders, for example rheumatoid arthritis, vasculitis, systemic lupus erythematosis, cutaneous lupus erythematosis, ulcerative colitis, cancer, cystic fibrosis, asthma, multiple sclerosis and psoriasis. The process of preparation of the compounds of Formula (I), (II), and (III), their polymorphs, stereoisomers, prodrugs, solvates, co-crystals, intermediates, pharmaceutically acceptable salts, and metabolites thereof, along with a pharmaceutical composition comprising a compound of Formula (I), Formula (II), Formula (III), or a pharmaceutically acceptable salt thereof have also been described.